Treatment with SIGNIFOR may lead to decreases in circulating levels of cortisol resulting in biochemical and/or clinical hypocortisolism. SIGNIFOR dose reduction or interruption and/or adding...
The information found within this section can be a valuable reference for health care professionals, patients, and caregivers who have an active role in the treatment and management of Cushing’s disease.
For additional support and guidance, talk to your Novartis sales representative about available SIGNIFOR and/or Cushing’s disease education references and tools.
Click on the video to hear Sara, a patient taking SIGNIFOR® (pasireotide) Injection, talk about living with Cushing's disease.
The following websites are good sources of information on Cushing's disease and Cushing's syndrome.
*Novartis Pharmaceuticals Corporation may make donations to these groups and organizations, but Novartis has no control over third-party websites and makes no representation as to the accuracy, completeness, adequacy, or any other aspects of the information contained on such websites.
View the patient website here
SIGNIFOR® (pasireotide) Injection, for subcutaneous use
SIGNIFOR is indicated for the treatment of adult patients with Cushing's disease for whom pituitary surgery is not an option or has not been curative.
IMPORTANT SAFETY INFORMATION
Warnings and Precautions:
The most common adverse reactions (frequency ≥20% in either group) occurring in patients receiving SIGNIFOR in clinical trials were:
Please see full Prescribing Information.